Building on shaky foundations? 'No way' says Sartorius
Award-winning building protected by special construction against vibration and temperature fluctuations.
Sartorius has officially opened it its approximately 42-million-euro building as part of Sartorius Campus for the manufacture of laboratory instruments. The new facility provides high-quality production conditions and an advanced, efficient work environment. Around 450 employees build laboratory instruments, such as balances, ultrapure water systems and moisture analysers at this facility covering about 25,000 m2 (270,000 sq. ft.) in the industrial zone of Grone in Goettingen.
The production facility, to which the State of Lower Saxony and the German federal government together contributed 4.2 million euro, represents the largest single investment of Sartorius Campus. On the whole, Sartorius is investing around 500 million euro in its Campus up to completion of construction scheduled for the end of 2018. The new Group headquarters will combine two Goettingen sites and, apart from providing more capacity for manufacture and administration, offers an attractive work environment. Moreover, the Campus grounds covering around 170,000 m2 (1,829,865 sq. ft.), can be used to further expand its facilities.
Speaking to CPHI-Online, Sartorius explained they made the significant investment so they could benefit from the increased capacity, both now and in the future. In addition, production times, which at the old site were very good, are now even better. The move to having everything under one roof has also positively affected production logistics.
The new building combines different manufacturing sites, formerly spread out at various locations, all under one roof: parts manufacture, prototype construction, calibration center, an extended vocational training workshop and an administration complex. Glass expanses of close to 7,000 m2 (75,350 sq. ft.), provide plenty of daylight throughout all areas of the building; a modern office design permits efficient work. As highly accurate balances are also calibrated inside, the building is protected from temperature fluctuations and protected by a foundation isolated from vibration by decoupling.
At the beginning of this year, the building won the 2017 Engineering Award of the German Structural Steel Industry, "Ingenieurpreis des Deutschen Stahlbaues" in the category of highrise building construction. The jury of the prize sponsor bauforumstahl e.V. lauded this construction as a symbol of the dynamics and solid quality workmanship of the laboratory balances manufactured at the facility. In addition, Sartorius is aiming to have this new building certified by the German Society for Sustainable Building, DGNB.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance